Phase 3 N=452 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Overall Survival (OS) — 13.5; 11.5 Months — p==0.0169
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients
Cancer-related Problem/Condition · Ambulatory Care
Primary: Patient Subject Questionnaire Post Shower Evaluation — 80; 88; 76; 0 percentage of yes responses
Phase 2 N=70 Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion
Acute Coronary Syndrome
Primary: Change in Percent Inhibition of Platelet Aggregation (%IPA) — 99.59; 99.88 percentage of IPA
Phase 2 N=26 Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection
Hepatitis C Infection With HIV Co-Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12) — 76.9 percentage of participants
N/A N=181 Addiction Housing Case Management for Homeless Veterans
Homelessness · Substance Abuse Disorders · Mental Disorders
Primary: Percent Days Housed in AHCM vs. HSG, Baseline to 12 Months. — 14.7; 12.0; 25.0; 14.1 percent days housed
Phase 3 N=745 Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants
Whole Cell Pertussis · Diphtheria · Hepatitis B
Primary: Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL — 39; 41; 37; 39 Participants
N/A N=684 Study Evaluating the Safety and Efficacy of Enbrel (Etanercept) in Japan
Rheumatoid Arthritis
Primary: Number of Participants in Safety Analysis Population of Etanercept — 676; 561; 676; 475 Participants
Phase 4 N=205 UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
Neovacular Age-related Macular Degeneration
Primary: Percent Change From Baseline at Month 3 in Plasma VEGF Following Intravitreal (IVT) Injection of Anti-VEGF Agent — 41.04; -21.53 Percent change — p=0.012
Phase 1 N=26 CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
Hematopoietic/Lymphoid Cancer · Adult Acute Lymphoblastic Leukemia in Remission · B-cell Adult Acute Lymphoblastic Leukemia
Primary: Number of Participants With Adverse Events — 20 participants
N/A N=5 CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis
Chronic Pancreatitis
Primary: Change in Pain Response Over a 6 Month Period of Time Using the VAS Score
Phase 2 N=9 Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Lymphoma
Primary: Clinical Response Rate — 2; 0; 1; 1 participants
N/A N=15 Functional Movement Retraining After Hip Replacement
Arthroplasty, Replacement, Hip
Primary: Change in Hip Disability and Osteoarthritis Outcomes Score (HOOS) - Activities of Daily Living Scale — -6.00 units on a scale
Phase 2 N=31 Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity in Phase I — 2; 0 participants with DLTs
Phase 2 N=46 Sorafenib and Vinorelbine in Treating Women With Stage IV Breast Cancer
Breast Cancer
Primary: Number of Participants With at Least One Dose Limiting Toxicity in Phase I — 0; 3 participants with DLTs
Phase 3 N=803 Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
Severe Aortic Stenosis · Transcatheter Aortic Valve Replacement · Aortic Valve Replacement
Primary: Major Bleeding (BARC ≥3b) at 48 Hours or Before Hospital Discharge — 6.9; 9 percentage of participants — p=0.2692